Trials / Completed
CompletedNCT03629782
Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,032 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-country, multicentre, observational cross-sectional one-visit study of patients suffering from severe asthma in primary and secondary care settings in Europe
Detailed description
This study aims to generate real-world data on the characteristics of patients considered to have severe asthma in primary and secondary care settings that should be referred for assessment for biologics. It is anticipated that these data from European countries, will help to estimate the unmet need for better treatments in severe asthma patients and will provide supporting evidence on the current shortcomings in referrals to asthma specialist or secondary care clinics. This information could also support the development of better severe asthma care pathways across Europe. Approximately 1,500 other patients like you will take part in the RECOGNISE study.
Conditions
Timeline
- Start date
- 2018-04-26
- Primary completion
- 2020-07-31
- Completion
- 2020-07-31
- First posted
- 2018-08-14
- Last updated
- 2021-02-21
Locations
12 sites across 12 countries: Bulgaria, Czechia, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Slovenia, Spain
Source: ClinicalTrials.gov record NCT03629782. Inclusion in this directory is not an endorsement.